The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).


Sun Myint, Arthur ORCID: 0000-0001-5323-5696, Rao, Christopher, Barbet, Nicolas, Thamphya, Brice, Pace-Loscos, Tanguy, Schiappa, Renaud, Magné, Nicolas, Martel-Lafay, Isabelle, Mineur, Laurent, Deberne, Melanie et al (show 3 more authors) (2023) The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750). Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 25 (11). pp. 2160-2169.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Aim</h4>Nonsurgical treatment with chemoradiotherapy for rectal cancer is gaining interest as it avoids total mesorectal excision (TME) surgery and stoma. The OPERA trial aims to evaluate whether dose escalation with contact X-ray brachytherapy (CXB) boost improves organ preservation compared to external beam radiotherapy (EBRT) boost. It has been suggested that dose escalation adversely affects surgical outcomes and therefore we report outcomes following TME in OPERA at 36 months.<h4>Methods</h4>OPERA is a European multicentre phase 3 trial (NCT02505750) which randomises patients with cT2-3a-b, cN0-1, M0 to EBCRT (45 Gy in 25 fractions over 5 weeks with oral capecitabine 825 mg/m<sup>2</sup> ) followed by EBRT boost (9 Gy in 5 fractions over 5 days) versus EBCRT followed by CXB boost (90 Gy in 3 fractions over 4 weeks). Patients were assessed at 14, 20 and 24 weeks from the start of treatment. Watch and wait management was adopted for patients who achieved a clinical complete response (cCR) at 24 weeks following treatment. Either local excision (LE) or TME surgery was offered for residual disease or local regrowth, according to patient and surgeon preference. Surgical morbidity and mortality were recorded prospectively.<h4>Results</h4>Between July 2015 and June 2020, 148 patients were randomised of which 141 were evaluable in March 2022. At median follow-up of 38.2 months (range: 34.2-42.5), surgery was performed for 66 (47%) patients. A total of 27 (20%) patients had local excision and 39 (29%) had TME surgery, 22/39 (56%) underwent anterior resection and 17/39 (44%) underwent abdominoperineal excision of the rectum. The R0 resection rate was 87%. There were no deaths, and six patients (15%) had Clavien-Dindo IIIb complications. Whilst there was a statistically significant decrease in the TME rate following CXB boost (HR 0.38, 95% CI: 0.19-0.74, p = 0.00419) there was no difference in surgical outcomes between patients who received EBRT and CXB boost.<h4>Conclusion</h4>Dose escalation can facilitate nonsurgical treatment for cT2-3 rectal cancer patients who are fit but wish to avoid TME surgery and stoma. If TME surgery is required, then it can be performed safely and effectively.

Item Type: Article
Uncontrolled Keywords: Humans, Adenocarcinoma, Rectal Neoplasms, Neoplasm Recurrence, Local, Organ Preservation, Treatment Outcome, Neoadjuvant Therapy, Chemoradiotherapy
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 18 Oct 2023 12:32
Last Modified: 24 Nov 2023 13:07
DOI: 10.1111/codi.16773
Open Access URL: https://doi.org/10.1111/codi.16773
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3173848
Dimensions
Altmetric
CORE (COnnecting REpositories)